Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026
Same author

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Blood advances·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Assessing patient perspectives on enrollment in lymphoma clinical trials.

Cancer·2026

Related Experiment Video

Updated: Jun 7, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Improving outcomes for patients with diffuse large B-cell lymphoma.

Christopher R Flowers1, Rajni Sinha, Julie M Vose

  • 1Bone Marrow and Stem Cell Transplantation, Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA. Barbara.Copeland@emoryhealthcare.org

CA: a Cancer Journal for Clinicians
|October 30, 2010
PubMed
Summary

Diffuse large B-cell lymphoma (DLBCL), a common non-Hodgkin lymphoma, is increasingly understood through gene expression profiling. Novel therapies combining chemotherapy and immunotherapy, like rituximab with CHOP, significantly improve outcomes for DLBCL patients.

Related Experiment Videos

Last Updated: Jun 7, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma in Western countries.
  • The etiology of most DLBCL cases remains unknown, despite increasing incidence across demographics.
  • DLBCL is characterized by an aggressive course but is potentially curable with chemotherapy.

Purpose of the Study:

  • To explore the biological heterogeneity of DLBCL.
  • To improve survival rates for DLBCL patients through novel therapeutic combinations.
  • To leverage gene expression profiling for prognostic and therapeutic insights.

Main Methods:

  • Gene expression profiling (GEP) to identify DLBCL subtypes.
  • Combination chemotherapy regimens, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).
  • Addition of immunotherapy, specifically the monoclonal antibody rituximab, to standard chemotherapy.

Main Results:

  • GEP has revealed distinct DLBCL subtypes with varying clinical behaviors and prognoses.
  • The addition of rituximab to CHOP chemotherapy has significantly improved patient outcomes.
  • Advancements in understanding DLBCL biology have led to improved survival rates.

Conclusions:

  • Gene expression profiling is crucial for understanding DLBCL heterogeneity and prognosis.
  • Immunochemotherapy, such as rituximab plus CHOP, represents a major advancement in DLBCL treatment.
  • Future DLBCL management will integrate molecular signatures for personalized therapy and target identification in relapsed or high-risk disease.